Current Collaborations


On July 28, 2016, Galmed entered into a license agreement with Samil Pharma. Co. Ltd. for the commercialization of Aramchol in Korea. Samil Pharma has an exclusive, royalty-bearing license for the commercialization of Aramchol™ for the treatment of fatty liver indications including nonalcoholic steatohepatitis (NASH) in Korea. Read More

On July 8, 2015, Galmed entered into a Research, Option and License Agreement with OWL, for the development of a non-invasive, blood-based complementary diagnostic tool, which we believe could increase the likelihood of success of our Phase III trials and facilitate the market adoption of Aramchol. Read More